ANDA 214348, held by Hengrui Pharma. Bupivacaine.
As of Nov 16, 2026, ANDA 214348 (Bupivacaine Liposome), held by Hengrui Pharma, was first approved by FDA on Jul 1, 2024, with 0 approved supplements and 0 published complete response letters.
1. INDICATIONS AND USAGE Bupivacaine liposome injectable suspension is indicated to produce postsurgical: Local analgesia via infiltration in adults Regional analgesia via an interscalene brachial plexus nerve block in adults Limitations of Use The safety and effectiveness of bupivacaine liposome injectable suspension have not been established to produce postsurgical regional analgesia via other nerve blocks besides an interscalene brachial plexus nerve block. Bupivacaine liposome injectable suspension contains bupivacaine, an amide local anesthetic, and is
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 1, 2024 | Original application | Approved |
| Bupivacaine Liposome133MG/10ML (13.3MG/ML) · injectable, liposomal;injection | Bupivacaine | Discontinued |
| Bupivacaine Liposome266MG/20ML (13.3MG/ML) · injectable, liposomal;injection | Bupivacaine | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters